Article

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA 02115, USA.
International journal of radiation oncology, biology, physics (Impact Factor: 4.18). 02/2010; 78(1):85-90. DOI: 10.1016/j.ijrobp.2009.07.1741
Source: PubMed

ABSTRACT Increasing evidence has suggested that angiogenesis inhibition might potentiate the effects of radiotherapy and chemotherapy in patients with glioblastoma (GBM). In addition, epidermal growth factor receptor inhibition might be of therapeutic benefit, because the epidermal growth factor receptor is upregulated in GBM and contributes to radiation resistance. We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ).
A total of 13 GBM patients were treated with vandetanib, radiotherapy, and concurrent and adjuvant TMZ, using a standard "3 + 3" dose escalation. The maximal tolerated dose was defined as the dose with <1 of 6 dose-limiting toxicities during the first 12 weeks of therapy. The eligible patients were adults with newly diagnosed GBM, Karnofsky performance status of >or=60, normal organ function, who were not taking enzyme-inducing antiepileptic drugs.
Of the 13 patients, 6 were treated with vandetanib at a dose of 200mg daily. Of the 6 patients, 3 developed dose-limiting toxicities within the first 12 weeks, including gastrointestinal hemorrhage and thrombocytopenia in 1 patient, neutropenia in 1 patient, and diverticulitis with gastrointestinal perforation in 1 patient. The other 7 patients were treated with 100 mg daily, with no dose-limiting toxicities observed, establishing this dose as the maximal tolerated dose combined with TMZ and RT.
Vandetanib can be safely combined with RT and TMZ in GBM patients. A Phase II study in which patients are randomized to vandetanib 100 mg daily with RT and TMZ or RT and TMZ alone is underway.

Download full-text

Full-text

Available from: Stephanie Elizabeth Weiss, Feb 21, 2015
0 Followers
 · 
124 Views
  • Source
    • "Recent reports suggest that directly targeting angiogenesis might increase the therapeutic ratio when being combined with irradiation (Beal et al. 2011). In accordance, the monoclonal antibody bevacizumab , which blocks angiogenesis by preventing the binding of VEGF to its respective receptor (Willett et al. 2004), significantly improves clinical outcome when combined with radiotherapy (Velenik et al. 2011; Shin et al. 2011; Niyazi et al. 2012a), and similar results were obtained for the VEGF-R inhibitor vandetanib and, primarily , for the antiangiogenetic peptide cilengitide (Albert et al. 2006; Williams et al. 2004; Brazelle et al. 2006; Drappatz et al. 2010; Yang et al. 2010). However, a recent phase III trial on cilengitide in combination with radiochemotherapy failed to show a significant increase in overall survival in glioblastoma patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on its potent capacity to induce tumor cell death and to abrogate clonogenic survival, radiotherapy is a key part of multimodal cancer treatment approaches. Numerous clinical trials have documented the clear correlation between improved local control and increased overall survival. However, despite all progress, the efficacy of radiation-based treatment approaches is still limited by different technological, biological, and clinical constraints. In principle, the following major issues can be distinguished: (1) The intrinsic radiation resistance of several tumors is higher than that of the surrounding normal tissue, (2) the true patho-anatomical borders of tumors or areas at risk are not perfectly identifiable, (3) the treatment volume cannot be adjusted properly during a given treatment series, and (4) the individual heterogeneity in terms of tumor and normal tissue responses toward irradiation is immense. At present, research efforts in radiation oncology follow three major tracks, in order to address these limitations: (1) implementation of molecularly targeted agents and 'omics'-based screening and stratification procedures, (2) improvement of treatment planning, imaging, and accuracy of dose application, and (3) clinical implementation of other types of radiation, including protons and heavy ions. Several of these strategies have already revealed promising improvements with regard to clinical outcome. Nevertheless, many open questions remain with individualization of treatment approaches being a key problem. In the present review, the current status of radiation-based cancer treatment with particular focus on novel aspects and developments that will influence the field of radiation oncology in the near future is summarized and discussed.
    Biophysik 10/2013; 53(1). DOI:10.1007/s00411-013-0497-2 · 1.58 Impact Factor
  • Source
    • "VEGFR Vandetanib Glioma [180] [181] VEGFR PTK787/ZK 222548 Glioma, hemangioblastoma [182] [183] VEGFR2 Cediranib, AZD2171 Brain metastases, CNS tumors [184] VEGFR2 CT-322 Glioma – however, other manifestations of tuberous sclerosis complex , especially lung function and neurological symptoms do not or only partially react to prolonged rapamycin treatment [62] [63]. The potential of prolonged rapamycin treatment to provoke full mTOR inhibition is undisputed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In cancer, genetic and epigenetic alterations ultimately culminate in discordant activation of signal transduction pathways driving the malignant process. Pharmacological or biological inhibition of such pathways holds significant promise with respect to devising rational therapy for cancer. Thus, technical concepts pursuing robust characterization of kinase activity in tissue samples from cancer patients have been subject of investigation. In the present review we provide a comprehensive overview of these techniques and discuss their advantages and disadvantages for systems biology approaches to identify kinase targets in oncological disease. Recent advances in the development and application of array-based peptide-substrate kinase activity screens show great promise in overcoming the discrepancy between the evaluation of aberrant cell signaling in specific malignancies or even individual patients and the currently available ensemble of highly specific targeted treatment strategies. These developments have the potential to result in a more effective selection of kinase inhibitors and thus optimize mechanism-based patient-specific therapeutic strategies. Given the results from current research on the tumor kinome, generating network views on aberrant tumor cell signaling is critical to meet this challenge.
    Critical reviews in oncology/hematology 06/2011; 82(2):171-86. DOI:10.1016/j.critrevonc.2011.05.002 · 4.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper reveals the main relations determined between the switching time, a value of the “preliminary” discharge current, hydrogen pressure and parameters of the external electrical circuit. Build-up rates of the anode current up to 7×10<sup>10 </sup> As<sup>-1</sup> are obtained. Pulse pumping generators for TEA-CO <sub>2</sub> lasers switching between average powers up to 15 kW at a pulse repetition rate up to 5 kHz are created
    Discharges and Electrical Insulation in Vacuum, 1996. Proceedings. ISDEIV., XVIIth International Symposium on; 08/1996
Show more